• News
  • Cases
  • Downloads
Taplow News
06.04.2020

Taplow News

The global pandemic has seen businesses affected across every sector, in all parts of the world. Taplow partners have combined to give insights...
January 2020– Singapore is primed for exceptional growth. Taplow Group is pleased to announce the formation of Taplow Singapore.
16.01.2020

January 2020– Singapore is primed for exceptional growth. Taplow Group is pleased to announce the formation of Taplow Singapore.

Singapore is a leading business hub for Asia and global markets. The Taplow Group S.A. is delighted to announce our new partner firm in Singapore.
Political Technology
27.12.2019

Political Technology

Technology is creating our future. Technology can be a blessing, but it can also be a threat, as it also is a leverage for power — such as...
12345678910Last

CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here